JKC 363

Product Name:JKC 363

CAS No:436083-30-6

Purity:95%

Molar Mass:1506.72

Chemical Formula:C69H91N19O16S2

Storage:Store at -20 degrees Celsius

Sequence:XEHXRWGCPPKD

Target:melanocortin MC4

Application:JKC 363 is a peptide that acts as a selective antagonist of the melanocortin-4 receptor (MC4R). MC4R is a key receptor involved in regulating appetite, energy balance, and metabolic processes. By inhibiting this receptor, JKC 363 can be used to study the role of MC4R in conditions like obesity and metabolic syndrome, where dysregulation of this receptor can lead to altered food intake and energy expenditure. The peptide is valuable in research aiming to understand the mechanisms behind appetite control and to develop potential treatments for metabolic disorders.

Current Research:

JKC-363 is a highly selective and potent antagonist of the melanocortin 4 receptor (MC4R), with an IC₅₀ of 0.5 nM. Its remarkable specificity, coupled with a significantly lower affinity for melanocortin 3 receptor (MC3R) (IC₅₀ = 44.9 nM), makes it an invaluable tool for studying MC4R-mediated physiological and pathological processes. MC4R plays a critical role in regulating energy homeostasis, neuroendocrine signaling, and pain modulation, making JKC-363 a focus of diverse research fields.

Metabolic and Appetite Regulation

One of the most extensively studied roles of JKC-363 is its involvement in metabolic processes and appetite regulation. MC4R is a key regulator of energy homeostasis, and its antagonism by JKC-363 has been shown to reduce appetite and alter food intake in animal models. Current research explores how selective MC4R inhibition can inform therapeutic strategies for treating metabolic disorders such as obesity. By modulating MC4R activity, researchers aim to achieve better appetite control without affecting related melanocortin pathways, reducing the risk of off-target effects.

Neuroendocrine and Thyroid Regulation

JKC-363 is also used to study the impact of MC4R on neuroendocrine signaling. In vivo studies demonstrate that JKC-363 suppresses the release of thyrotropin-releasing hormone (TRH), highlighting its role in thyroid function regulation. This property has opened avenues to explore MC4R as a potential target for managing disorders of the hypothalamic-pituitary-thyroid axis.

Pain Modulation

Recent investigations have identified JKC-363’s anti-hyperalgesic effects, suggesting that MC4R antagonism could serve as a therapeutic approach for pain management. These findings contribute to understanding how melanocortin pathways influence pain sensitivity and inflammation.

Conclusion

JKC-363 is a vital research tool in elucidating the complex roles of MC4R in energy regulation, neuroendocrine signaling, and pain pathways. Its application continues to advance therapeutic research for metabolic, endocrine, and pain-related disorders.

Reference:

Kim, R. Y., Shin, S. W., Kim, B. J., Lee, W., & Baik, J. H. (2005). Dynamic regulation of hypothalamic neuropeptide gene expression and food intake by melanocortin analogues and reversal with melanocortin-4 receptor antagonist. Biochemical and biophysical research communications, 329(4), 1178-1185.